Munson Health
 
Fabry Disease

Back to Document

by Badash M

(Alpha-Galactosidase A Deficiency; Anderson-Fabry Disease; Angiokeratoma Corporis Diffusum; Angiokeratoma Diffuse; Ceramide Trihexosidase Deficiency; GLA Deficiency; Glycolipid Lipidosis; Hereditary Dystopic Lipidosis)

 

RESOURCES

Fabry Support and Information Group (FSIG)
http://www.fabry.org

National Institute of Neurological Disorders and Stroke
http://www.ninds.nih.gov

 

CANADIAN RESOURCES

Canadian Fabry Association
http://www.fabrycanada.com

Health Canada
http://www.hc-sc.gc.ca

 

References


Fabry disease. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated July 10, 2014. Accessed July 13, 2014.


Martins AM, D’Almeida V, Kyosen SO, et al. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatrics. 2009;155(4 Suppl):S19-S31.


NINDS Fabry disease information page. National Institute of Neurological Disorders and Stroke website. Available at: http://www.ninds.nih.gov/disorders/fabrys/fabrys.htm. Updated October 6, 2011. Accessed August 14, 2013.


12/20/2007 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: 2007 safety alerts for drugs, biologics, medical devices, and dietary supplements: Carbamazepine (marketed as Carbatrol, Equetro, Tegretol and generics). Medwatch. US Food and Drug Administration website. Available at: http://www.fda.gov/medwatch/safety/2007/safety07.htm#carbamazepine.


7/13/2014 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed. Laney DA, Bennett RL, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2013 Oct;22(5):555-564.

 

Revision Information